Summary Reserpine was found to enhance the cytotoxicity of ACNU on ACNU-resistant C6 glioma (C6/ACNU) cells in vitro. When reserpine was added along with ACNU to the C6/ACNU cells in vitro. When reserpine was added along with ACNU to the C6/ACNU culture in vitro at a concentration of 10JM, the IC50 of ACNU for C6/ACNU cells decreased to the level of that for C6 cells and ACNU resistance was completely overcome in vitro. Furthermore, intracellular uptake of ACNU increased in both sensitive (C6) and resistant (C6/ACNU) glioma cells when 2OJM reserpine was added to the culture medium. Reserpine (20 M) enhanced the cellular level of ACNU in C6 cells 1.5-fold and enhanced the level of ACNU in C6/ACNU cells 4-fold. The amount of ACNU incorporated into C6/ACNU cells reached the same level as that incorporated into C6 cells. The enhanced cytotoxicity of ACNU in vitro could be explained by the effective intracellular accumulation of ACNU resulting from the increase of intracellular uptake of ACNU in C6/ACNU cells by reserpine.
One of the most serious problems in the chemotherapy of malignant tumours is that tumour cells are rapidly able to acquire resistance to initially effective chemotherapeutic agents (Salmon et al., 1978) . A nitrosourea derivative 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), is sometimes used with other nitrosourea derivatives in the chemotherapy of brain tumours and shows considerable efficacy, because it easily crosses the blood-brain barrier (BBB) (Shimizu et al., 1980; Ushio et al., 1981) . Recently, however, the emergence of variant cells resistant to ACNU has become a controversial issue in brain tumour chemotherapy (Aida et al., 1985; Kokunai et al., 1985; Yoshida et al., 1984) . In spite of the importance of resistance in the chemotherapy of brain tumours, research in this field is limited. Apart from our report (Yoshida et al., 1984) , there is little information in the literature regarding drug resistance in malignant brain tumours (Aida et al., 1985; Kokunai et al., 1985; Merry et al., 1984) .
In order to investigate the mechanism of resistance to ACNU in brain tumours and the possibility of overcoming ACNU resistance, we have selected, in vivo, a variant subline resistant to ACNU from rat C6 glioma cells. We have also studied the intracellular uptake of ACNU in ACNU-resistant C6 glioma (C6/ACNU) cells. 
Materials and methods
Tumours and animals Male Wistar rats weighing 100 g were used in experiments. A subline of C6 glioma resistant to ACNU (C6/ACNU) was developed by treating Wistar rats in which 1 x 107 of C6 glioma cells were transplanted percutaneously into the cisterna magna with ACNU (1 mg kg 1, intrathecally, i.t.) over successive transplant generations, as previously described (Yoshida et al., 1984) . Complete resistance in vivo to maximally tolerated doses of ACNU was evident after a 2nd transplant generation of exposure to the drug. After 5 generations of drug exposure, the ACNU-resistant line was split into two sublines; one was maintained in drug-treated rats and the other was transplanted without further drug treatment. Resistance At various time intervals, the culture medium was discarded and the cells were washed 3 times with 1 ml of cold PBS. The cells were lysed overnight with 400 1 of I N NaOH and 60Oul of 9 N HCI was added in the wells. The lysates were transferred to scintillation vials containing 7 ml of scintillator (Univer Gel-2, Nakarai Chemical Co., Kyoto, Japan), and the radioactivity was counted in a liquid scintillation spectrometer (Mark 3, 6881 Liquid Scintillation System, Tracor Analytic). The amount of drug incorporated into the cells was expressed as pmol 10-I cells.
Results
Enhanced cytotoxicity of ACNU in C6 and C6/ACNU cells by reserpine The sensitivities of C6 and C6/ACNU cells to ACNU and the effect of reserpine on the sensitivity are illustrated in Figure 1 and Table I 
Discussion
The development of variant cell lines that are resistant to chemotherapeutic drugs, including ACNU, is a frequent complication in chemotherapy (Salmon et al., 1978; Yoshida et al., 1984) . Although many investigators have studied drug resistance in various tumour cell lines, there are only a few reports of drug resistance in brain tumours (Aida et al., 1985; Kokunai et al., 1985; Merry et al., 1984) . We have previously isolated and propagated in vivo a variant cell line of rat C6 glioma that is highly resistant to the cytotoxic action of ACNU (Yoshida et al., 1984) . In the induction of ACNU resistance in vivo, emphasis was placed on the development of resistance in the course of therapy with ACNU as the selection of resistant cells in this manner is thought to be more realistic. In the present study, the cellular concentrations of ACNU in C6/ACNU cells were almost 4 times lower than those found in C6 cells. Reserpine has enhanced the cytotoxicity of ACNU in C6/ACNU cells, and could completely overcome ACNU resistance in vitro. At a nontoxic dose of 20 gM of reserpine, the cellular level of ACNU in C6/ACNU cells increased to almost the same extent as that in C6 cells (Figure 2) . Actually, in in vitro experiments, the sensitivities of C6 and C6/ACNU cells to ACNU were almost equal when 1O0M reserpine was added along with ACNU to the culture (Figure 1 , Table I ).
While examining a number of membrane interacting agents, it was found that reserpine enhances the cytotoxicity of ACNU in ACNU-resistant glioma cells and increases the intracellular uptake of ACNU in the cells. The mechanism of enhancement of the cytotoxicity of ACNU in C6/ACNU cells by reserpine is not known. However, Koshiura et al. (1980) discovered the enhanced effect of the chemotherapeutic agent 1-(gamma-chloropropyl)-2-chloromethylpyrimidine hydrochloride (CAP-2), in AH-13 and AH-44 cells by reserpine and reported the mechanism to be inhibition of DNA repair.
Contrary to this report, we showed an increase of 775 cellular uptake of ACNU in both C6 and C6/ACNU cells treated with reserpine. It is suggested that the enhanced effect of the cytotoxicity of ACNU in C6/ACNU cells is due to the increase of intracellular ACNU. This is supported by Inaba et al. (1981) to the effect that reserpine circumvented resistance to adriamycin and vincristine in P388 leukaemia cells. As for the actions of reserpine, antitumour activity against hypoxic cells was also reported (Lehnert, 1982) , but the precise mechanism of this activity has not been clarified. On the other hand, it has been disclosed that reserpine decreases the amount of calcium in the heart, blood vessels and brain (Carrier et al., 1970; Ross et al., 1974) , and that calcium bound to lipid of cell membranes is released by reserpine (Wang & Radouco-Thomas, 1978) . Recently, Tsuruo et al. (1983) reported that the mechanism of drug resistance is due to both the reduced uptake of the drug and the increased active efflux of the intracellular drug from the resistant cells showing the intracellular accumulation of the drug by calcium antagonists. They have stressed that the mechanism of drug resistance is profoundly related to cell membrane calcium metabolism and calmodulin. The results of the present experiment are consistent with their observation of reduced cellular uptake of the drug in the resistant cells. Furthermore, the enhanced cytotoxicity of ACNU by reserpine could be explained by their hypothesis, if reserpine acts on the membrane as a calcium antagonist as reported previously. However, the data in the present study indicated an almost 50-fold reduction in the IC50 (for 20pM reserpine) in association with a four-fold increase in drug uptake. Although the enhanced effect of the cytotoxicity of ACNU could be partially explained by the increased cellular drug level, it is conceivable that other mechanisms also apply. Kokunai et al. (1985) reported that ACNU resistance in 9L glioma is due to the increased DNA repair. Aida et al. (1985) also referred to the increase of DNA repair in an ACNU-resistant human glioma cell line in which the activity of 06-methyl guanine (06-mGua) DNA methyltransferase was high, and they reported that the increased activity of this enzyme is one of the causes of ACNU resistance in HU-188 human glioma. On these considerations, drug resistance is multifactorial and involves calcium, the enzymes related to calcium metabolism and cyclic AMP of the cell membranes (Inaba et al., 1981) and DNA repair (Aida et al., 1985; Kokunai et al., 1985) . Although the enhanced effect of the cytotoxicity of ACNU by reserpine presented herein might also be related to these factors, it has been shown that the mechanism of the enhanced effect of reserpine is partially due to the increase of the cellular accumulation of ACNU. The mechanism of ACNU resistance has not been elucidated. However, it seems that it is closely related to reduced uptake of ACNU as advocated in the present study. In order to investigate further the mechanism involved in ACNU resistance in C6/ACNU glioma, drug efflux in relation to reserpine should be measured.
It might be very difficult to explain the mechanism of drug resistance by a single mechanism as it is generally considered that the cause of drug resistance differs depending on the type of tumour and the drug. However, we are currently attempting to overcome ACNU resistance in rat brain tumour models using the same cell lines as those used in the present experiment. Moreover, we are investigating the exact basis of ACNU resistance by drug uptake and efflux studies in ACNU-resistant glioma cell lines.
